JBIO (JBIO) Stock Price & Analysis
JBIO (JBIO) fell 0.28% to USD 19.85 as of September 8, 2026 at 17:48 UTC, according to Nexqual real-time market data.
JBIO last closed at USD 19.85; the session ranged USD 19–20.15 on volume of 368,394 shares. Market capitalization is —, with a 52-week range of USD 6.91–28 (NCM). Source: Nexqual, September 8, 2026 at 17:48 UTC.
Key Statistics (as of September 8, 2026 at 17:48 UTC)
| Price | USD 19.85 |
|---|---|
| Change | ▼ 0.28% (down) |
| Previous Close | USD 19.85 |
| Open | USD 19.85 |
| Day Range | USD 19 – 20.15 |
| 52-Week Range | USD 6.91 – 28 |
| Volume | 368,394 shares |
| Market Cap | — |
| Exchange | NCM |
Technical Analysis (JBIO)
Nexqual's technical model rates JBIO "SELL" based on 1 bullish and 5 bearish signals across 127 daily candles, as of September 8, 2026 at 17:48 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 41.19 (neutral) |
| vs SMA50 | Below (USD 21.32) |
| MACD | -0.32 (negative) |
From JBIO's Latest SEC 10-K Filing (filed 2026-03-06)
Source: SEC EDGAR 10-K. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| GLUE | Monte Rosa Therapeutics, Inc. | USD 14.03 | ▼ 2.43% |
| TYRA | Tyra Biosciences, Inc. | USD 27.66 | ▲ 11.24% |
| DSGN | Design Therapeutics, Inc. | USD 15.16 | ▲ 0.86% |
| ABOS | Acumen Pharmaceuticals, Inc. | USD 3.22 | ▲ 4.21% |
| EWTX | Edgewise Therapeutics, Inc. | USD 44.34 | ▲ 5.7% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 17:48 UTC. This page is informational and not investment advice.